At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
MEDI-528 9 mg/kg +1 morebiological
Likely dose
MEDI-528 9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma
In Brief
A Phase 2 clinical trial evaluating MEDI-528 9 mg/kg and Placebo for Asthma. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartNov 2006
Primary CompletionAug 2007
Study CompletionJan 2008
TodayJul 2026
First PostedNov 1, 2006
Enrollment StartNov 1, 2006
Primary CompletionAug 1, 2007
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.7 years ago
Interventions
MEDI-528 9 mg/kgbiological
MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
Placeboother
Placebo administered as a single intravenous infusion